Brokerages predict that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce $6.69 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.80 million and the lowest estimate coming in at $4.50 million. Pieris Pharmaceuticals reported sales of $18.15 million in the same quarter last year, which indicates a negative year-over-year growth rate of 63.1%. The business is expected to announce its next quarterly earnings results on Friday, March 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.66 million for the current fiscal year, with estimates ranging from $28.70 million to $33.00 million. For the next fiscal year, analysts expect that the company will post sales of $22.74 million, with estimates ranging from $12.00 million to $31.00 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.04. The firm had revenue of $8.35 million for the quarter, compared to the consensus estimate of $6.16 million. Pieris Pharmaceuticals had a negative return on equity of 18.07% and a negative net margin of 17.90%.

A number of equities analysts have recently issued reports on the company. ValuEngine downgraded Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. BidaskClub downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Cowen restated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Sunday. Finally, HC Wainwright set a $12.00 price target on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Pieris Pharmaceuticals has an average rating of “Buy” and an average price target of $10.00.

In related news, Director Christopher P. Kiritsy bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The shares were bought at an average cost of $5.11 per share, with a total value of $25,550.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $51,100. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.07% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $110,000. Marshall Wace LLP bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $118,000. Fox Run Management L.L.C. bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $124,000. Bowling Portfolio Management LLC bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $156,000. Finally, California Public Employees Retirement System bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $179,000. 65.22% of the stock is currently owned by institutional investors.

Shares of PIRS stock traded up $0.07 on Monday, reaching $3.38. The stock had a trading volume of 444,532 shares, compared to its average volume of 607,637. The company has a market cap of $178.15 million, a P/E ratio of -8.45 and a beta of 1.94. Pieris Pharmaceuticals has a 1 year low of $3.04 and a 1 year high of $9.75.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: Cost of Capital Explained

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.